Aurobindo Pharma appoints T Vijaya Kumar as President - RnD (Specialty Drug Delivery)
Hyderabad: Aurobindo Pharma has appointed T. Vijaya Kumar as President - R&D (Specialty Drug Delivery). Accordingly, T. Vijaya Kumar will be part of the Senior Management team of the Company.
"The Company hereby inform that upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has appointed Mr. T. Vijaya Kumar as President – R&D (Specialty Drug Delivery) effective April 5, 2024," Aurobindo Pharma stated in a BSE filing.
T. Vijaya Kumar holds M. Pharm. (Masters in Pharmacy) Post-Graduation in Pharmacy from Gulbarga University, Gulbarga (India) with specialization in Pharmaceutical Technology. He has around 30 years’ experience in Pharma industry. He received prestigious Global Desh Bandhu Gupta Spirit of Lupin Award 2022 for the Value – “Passion for Excellence.”
Read also: Aurobindo Pharma bags USFDA nod for Mometasone Furoate Monohydrate Nasal Spray
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 25 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, AntiRetroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.
Read also: Aurobindo Pharma commissions 4 manufacturing plants for PenicillinG, other products
